Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Yalu Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5939-6685; OpenAlex author ID A5068864772. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: none · 2021: 5 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. ABHD17C-Mediated S-Depalmitoylation of BCL6B Enhances CD24 Transcription to Resist Macrophage Phagocytosis in Pancreatic Cancer. Co-author DOI 10.1002/advs.75757↗
  2. Pancreatic cancer cells escape T/NK cell immune surveillance through the expressional separation of CD58. Co-author DOI 10.1136/jitc-2025-012163↗
  3. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. Co-author DOI 10.1016/j.canlet.2024.217289↗
  4. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. First author DOI 10.3389/fonc.2022.968610↗
  5. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Co-author DOI 10.1007/s00262-020-02816-0↗
  6. Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omto.2021.08.012↗
  7. Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy. Co-author DOI 10.1186/s12935-021-01824-z↗
  8. Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-02037-0↗
  9. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.774435↗
  10. Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/jca.26207↗
  11. EFNB2 acts as the target of miR-557 to facilitate cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma by bioinformatics analysis and… Co-author PMID 30662604↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiaofei Liu · 7 shared papers, 2021–2025 · strength 1.28
  2. Sen Yang · 5 shared papers, 2021–2025 · strength 0.90
  3. Quan Liao · 5 shared papers, 2021–2025 · strength 0.88
  4. Ming Cui · 5 shared papers, 2021–2024 · strength 0.75
  5. Junyi Gao · 4 shared papers, 2021–2024 · strength 0.61
  6. Ronghua Zhang · 3 shared papers, 2021–2025 · strength 0.55
  7. Quan Liao · 3 shared papers, 2021–2024 · strength 0.52
  8. Jingkai Liu · 3 shared papers, 2021 · strength 0.46
  9. Tong Li · 3 shared papers, 2021–2024 · strength 0.44
  10. Jorg H. Kleeff · 2 shared papers, 2024–2025 · strength 0.43
  11. Mengyi Wang · 2 shared papers, 2021–2022 · strength 0.31
  12. Lianxin Liu · 1 shared paper, 2026 · strength 0.29
  13. Xiang Zhang · 2 shared papers, 2021 · strength 0.26
  14. Huaijin Zheng · 1 shared paper, 2025 · strength 0.26
  15. Kaixing Ai · 2 shared papers, 2018 · strength 0.23
  16. Junya Peng · 1 shared paper, 2024 · strength 0.18
  17. Surong Hua · 1 shared paper, 2021 · strength 0.15
  18. Rundong Zhang · 1 shared paper, 2018 · strength 0.12
  19. Guopei Luo · 1 shared paper, 2018 · strength 0.12
  20. Qiaofei Liu · 1 shared paper, 2021 · strength 0.12
  21. Huanwen Wu · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.